South Africa Tuberculosis Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Test, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
South Africa · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$17.3 MnPlaceholder estimate
Estimate 2025$18.5 Mn0.7% of the global market
Projected 2034$34.6 Mn 87%Adds $16.1 Mn over 9 forecast years
CAGR 2025–20347.2%Faster than 13% of 173 Medical Devices markets here
Key players5
South Africa is 0.72% of the global market.
In Africa, the largest is South Africa (this report) at $18.5 Mn.
49 in South AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The South Africa Tuberculosis Diagnostics Market Analysis Executive Summary
Tuberculosis diagnostics find TB infection and disease using skin tests, blood tests, molecular tests and chest X-ray reading.
Key segments of the tuberculosis Diagnostics market include test (Molecular Tests, Interferon Gamma Release Assays and Skin Tests) and setting (Hospitals, TB Programs and Point of Care).
South Africa Tuberculosis Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
South Africa Tuberculosis Diagnostics Market Dynamics
Market Growth Drivers
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the tuberculosis Diagnostics market.
Opportunity
Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the tuberculosis Diagnostics market room to grow, especially in emerging markets.
Market Restraints
Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the tuberculosis Diagnostics market.
Competitive Landscape for Tuberculosis Diagnostics Market in South Africa
The tuberculosis Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Tuberculosis Diagnostics Market in South Africa
Tuberculosis Diagnostics in South Africa: rules, payment and research
The South African Health Products Regulatory Authority (SAHPRA) regulates medical devices, starting with licences for the companies that make, import and sell them.[1] Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone.[2] ClinicalTrials.gov lists 49 studies on Tuberculosis Diagnostics that are recruiting, active or about to start in South Africa.[3] Tuberculosis new cases: 389 per 100,000 people in 2024, the latest World Bank figure for South Africa.[4]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
[4]World Bank Open Data, Tuberculosis new cases (per 100,000 people). Retrieved 19 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how tuberculosis Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in South Africa.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Test
4.2 By Setting
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Cepheid (Danaher)
7.2 QIAGEN
7.3 Molbio Diagnostics
7.4 Qure.ai
7.5 Revvity
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The tuberculosis Diagnostics market can be segmented based on various criteria, including test, setting and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: WHO Prequalification, Vaccines, tests and medicines on the WHO prequalified lists that match this market. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Tuberculosis Diagnostics right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 19 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Tuberculosis Diagnostics in context
South Africa compared
Tuberculosis new cases: 389 per 100,000 people (2024). World: 131 per 100,000 people (2024). Highest of the 17 countries we cover in Africa.[1]
Health spending per person: 537 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 17 countries we cover in Africa.[2]
Doctors: 0.79 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 17 countries we cover in Africa.[3]
[1]World Bank Open Data, Tuberculosis new cases (per 100,000 people). Retrieved 19 Nov 2026.
[2]World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.
How big is the Tuberculosis Diagnostics market in South Africa?
Placeholder estimate: about $18.5 Mn in 2025, rising to about $34.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Tuberculosis Diagnostics market in South Africa growing?
Placeholder estimate: about 7.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Tuberculosis Diagnostics market report cover?
The report splits the market by test (Molecular Tests, Interferon Gamma Release Assays, Skin Tests, Sputum Smear and more), setting (Hospitals, TB Programs, Point of Care) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Tuberculosis Diagnostics market?
Key players include Cepheid, Qiagen N.V., Molbio Diagnostics, Qure.ai and Revvity.
What is driving the Tuberculosis Diagnostics market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the tuberculosis Diagnostics market.
Who regulates Tuberculosis Diagnostics in South Africa?
The South African Health Products Regulatory Authority (SAHPRA) regulates medical devices, starting with licences for the companies that make, import and sell them. Source: South African Health Products Regulatory Authority. Checked 14 Nov 2026.
How is healthcare paid for in South Africa?
Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone. Source: National Department of Health. Checked 14 Nov 2026.
How many clinical trials on Tuberculosis Diagnostics are running in South Africa?
49 studies are recruiting, active or about to start in South Africa, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
What does World Bank report for South Africa?
Tuberculosis new cases: 389 per 100,000 people in 2024, the latest World Bank figure. Source: World Bank Open Data, Tuberculosis new cases (per 100,000 people). Retrieved 19 Nov 2026.
How many people in South Africa are 65 or older?
6.9% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 18 Nov 2026.